Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 55-9 (September 2025)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Titre : Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Craig ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul S. HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur Article en page(s) : p.3387-3394 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566 [article] Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder [texte imprimé] / Craig ERICKSON, Auteur ; Rebecca C. SHAFFER, Auteur ; Meredith WILL, Auteur ; Lauren M. SCHMITT, Auteur ; Paul S. HORN, Auteur ; Kathy HIRST, Auteur ; Ernest V. PEDAPATI, Auteur ; Nicole OBER, Auteur ; Rameshwari V. TUMULURU, Auteur ; Benjamin L. HANDEN, Auteur ; David Q. BEVERSDORF, Auteur . - p.3387-3394. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3387-3394 Index. décimale : PER Périodiques Résumé : Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12-22 year olds (mean age 17.4 years; range 12.9-22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug. En ligne : https://doi.org/10.1007/s10803-023-06132-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566

Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder / Luc LECAVALIER in Journal of Autism and Developmental Disorders, 48-4 (April 2018)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 48-4 (April 2018) . - p.980-987 Titre : Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Luc LECAVALIER, Auteur ; Xueliang PAN, Auteur ; Tristram SMITH, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Laura SILVERMAN, Auteur ; Rameshwari V. TUMULURU, Auteur ; Jill HOLLWAY, Auteur ; Michael G. AMAN, Auteur Article en page(s) : p.980-987 Langues : Anglais (eng) Mots-clés : Atomoxetine  Attention deficit hyperactivity disorder  Autism spectrum disorder  Parent stress  Parent training Index. décimale : PER Périodiques Résumé : We previously reported a 2 x 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions. All four treatments improved parent self-rated stress from baseline to week 10. However, there were no statistically significant differences between treatment groups. Significantly more improvement in parent stress scores was observed for clinical responders than non-responders. ClinicalTrials.gov Title: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) ClinicalTrials.gov Identifier: NCT00844753. En ligne : http://dx.doi.org/10.1007/s10803-017-3345-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=351 [article] Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder [texte imprimé] / Luc LECAVALIER, Auteur ; Xueliang PAN, Auteur ; Tristram SMITH, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Laura SILVERMAN, Auteur ; Rameshwari V. TUMULURU, Auteur ; Jill HOLLWAY, Auteur ; Michael G. AMAN, Auteur . - p.980-987. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 48-4 (April 2018) . - p.980-987 Mots-clés : Atomoxetine  Attention deficit hyperactivity disorder  Autism spectrum disorder  Parent stress  Parent training Index. décimale : PER Périodiques Résumé : We previously reported a 2 x 2 randomized clinical trial of atomoxetine (ATX) and parent training (PT) for attention deficit hyperactivity disorder (ADHD) symptoms and behavioral noncompliance in 128 children with autism spectrum disorder, ages 5-14 years. Children were randomized to one of four conditions: ATX alone, placebo alone, ATX + PT, or PT + placebo. Both ATX and PT improved some indices of ADHD and behavioral compliance. In this report, we describe parent stress over time and across conditions. All four treatments improved parent self-rated stress from baseline to week 10. However, there were no statistically significant differences between treatment groups. Significantly more improvement in parent stress scores was observed for clinical responders than non-responders. ClinicalTrials.gov Title: Atomoxetine, Placebo and Parent Management Training in Autism (Strattera) ClinicalTrials.gov Identifier: NCT00844753. En ligne : http://dx.doi.org/10.1007/s10803-017-3345-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=351

---

1 (1 - 2 / 2) Par page : 25 50 100 200